Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Education | $134.94 | 2 | 51.8% |
| Food and Beverage | $125.52 | 4 | 48.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $99.99 | 1 | $0 (2020) |
| Janssen Scientific Affairs, LLC | $85.43 | 1 | $0 (2017) |
| PFIZER INC. | $34.95 | 1 | $0 (2018) |
| LEO Pharma Inc. | $28.14 | 2 | $0 (2019) |
| EPI Health, LLC | $11.95 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $11.95 | 1 | EPI Health, LLC ($11.95) |
| 2020 | $99.99 | 1 | Janssen Biotech, Inc. ($99.99) |
| 2019 | $16.00 | 1 | LEO Pharma Inc. ($16.00) |
| 2018 | $47.09 | 2 | PFIZER INC. ($34.95) |
| 2017 | $85.43 | 1 | Janssen Scientific Affairs, LLC ($85.43) |
All Payment Transactions
6 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/04/2022 | EPI Health, LLC | CLODERM (Drug), MINOLIRA EXTENDED RELEASE, WYNZORA | Food and Beverage | In-kind items and services | $11.95 | General |
| Category: DERMATOLOGY | ||||||
| 12/17/2020 | Janssen Biotech, Inc. | TREMFYA (Drug) | Education | In-kind items and services | $99.99 | General |
| Category: Immunology | ||||||
| 01/28/2019 | LEO Pharma Inc. | ENSTILAR (Drug) | Food and Beverage | In-kind items and services | $16.00 | General |
| Category: DERMATOLOGY | ||||||
| 11/13/2018 | PFIZER INC. | EUCRISA (Drug) | Education | In-kind items and services | $34.95 | General |
| Category: DERMATOLOGY | ||||||
| 09/12/2018 | LEO Pharma Inc. | ENSTILAR (Drug) | Food and Beverage | In-kind items and services | $12.14 | General |
| Category: DERMATOLOGY | ||||||
| 10/19/2017 | Janssen Scientific Affairs, LLC | STELARA (Biological) | Food and Beverage | In-kind items and services | $85.43 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 1,849 | 2,971 | $499,968 | $146,295 |
| 2022 | 16 | 1,891 | 3,117 | $521,615 | $154,482 |
| 2021 | 18 | 2,111 | 3,266 | $620,284 | $176,169 |
| 2020 | 17 | 1,886 | 2,808 | $568,680 | $137,220 |
All Medicare Procedures & Services
66 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 612 | 843 | $179,438 | $52,755 | 29.4% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 378 | 585 | $93,759 | $27,098 | 28.9% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 158 | 192 | $47,112 | $14,864 | 31.6% |
| 12032 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | Office | 2023 | 38 | 47 | $34,230 | $11,178 | 32.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 104 | 121 | $36,297 | $10,650 | 29.3% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 88 | 94 | $25,599 | $7,972 | 31.1% |
| 11603 | Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm | Office | 2023 | 30 | 38 | $25,220 | $5,194 | 20.6% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 247 | 816 | $13,056 | $4,189 | 32.1% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 68 | 73 | $9,748 | $3,065 | 31.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 36 | 36 | $9,492 | $2,472 | 26.0% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 26 | 26 | $7,958 | $2,157 | 27.1% |
| 17262 | Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | Office | 2023 | 14 | 15 | $6,378 | $2,104 | 33.0% |
| 11602 | Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | Office | 2023 | 15 | 15 | $8,774 | $1,612 | 18.4% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 22 | 23 | $2,813 | $955.19 | 34.0% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 13 | 47 | $94.00 | $32.00 | 34.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 644 | 893 | $191,743 | $57,036 | 29.7% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 362 | 585 | $92,417 | $26,615 | 28.8% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 147 | 169 | $41,991 | $13,420 | 32.0% |
| 12032 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | Office | 2022 | 35 | 46 | $33,877 | $11,586 | 34.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 96 | 111 | $33,731 | $10,278 | 30.5% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 95 | 111 | $30,217 | $9,499 | 31.4% |
| 11104 | Punch biopsy, first skin growth | Office | 2022 | 70 | 77 | $23,954 | $7,432 | 31.0% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 235 | 834 | $13,344 | $4,426 | 33.2% |
| 11603 | Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm | Office | 2022 | 18 | 22 | $14,754 | $2,926 | 19.8% |
| 11602 | Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | Office | 2022 | 23 | 26 | $15,332 | $2,875 | 18.8% |
About Dr. Jon Solis, MD
Dr. Jon Solis, MD is a Dermatology healthcare provider based in Westerly, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/08/2005. The National Provider Identifier (NPI) number assigned to this provider is 1184622714.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jon Solis, MD has received a total of $260.46 in payments from pharmaceutical and medical device companies, with $11.95 received in 2022. These payments were reported across 6 transactions from 5 companies. The most common payment nature is "Education" ($134.94).
As a Medicare-enrolled provider, Solis has provided services to 7,737 Medicare beneficiaries, totaling 12,162 services with total Medicare billing of $614,166. Data is available for 4 years (2020–2023), covering 66 distinct procedure/service records.
Practice Information
- Specialty Dermatology
- Location Westerly, RI
- Active Since 07/08/2005
- Last Updated 02/26/2009
- Taxonomy Code 207N00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1184622714
Products in Payments
- TREMFYA (Drug) $99.99
- STELARA (Biological) $85.43
- EUCRISA (Drug) $34.95
- ENSTILAR (Drug) $28.14
- CLODERM (Drug) $11.95
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.